Anapharm Europe.

Anapharm Europe, PharmaNet officially terminate jv PharmaNet Development Group, Inc. And Anapharm Europe, S .L., both leading providers of drug development providers to the pharmaceutical, biotechnology, generic drug and medical device sectors, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010. With the termination of the romantic relationship, Dr. Maria Cruz Caturla, Anapharm Europe’s majority shareholder, has bought PharmaNet’s minority ownership curiosity, becoming the sole owner of the business thus.


Ancon Technologies unveils new cancer-screening device Ancon Technologies, a company devoted to finding new methods to beat cancer, recently unveiled a fresh cancer-screening device to the public, the NBT detector. The business's latest product aims to bring tumor detection to another level: it uses Nanoparticle Biomarker Tagging technology to identify malignancy biomarkers in exhaled atmosphere. According to the NBT detector's Indiegogo page, exhaled breath contains a distinctive mixture of molecules that are made by body liquids. Nanoparticle Biomarker Tagging recognition technology is a development that reads molecules emitted from a person's breath and uses it to identify the existence of illnesses.

Other entries from category "medicine":

Tag Cloud